Longitudinal Pharmacokinetic, Pharmacodynamic, Immunological, and Biochemical Sample Collection With MRI and Relapse Analysis of a Tysabri Patient Cohort.
Phase of Trial: Phase IV
Latest Information Update: 05 Jun 2015
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Biomarker; Pharmacokinetics
- 07 Jun 2017 Biomarkers information updated
- 05 Jan 2012 Additional lead trial centre (Biogen Idec) identified as reported by ClinicalTrials.gov.
- 05 Jan 2012 Company (Biogen Idec) added as trial sponsor/affiliate as reported by ClinicalTrials.gov.